Heterologous prime-boost vaccination with adenoviral vector and protein nanoparticles induces both Th1 and Th2 responses against Middle East respiratory syndrome coronavirus. (Q54217812)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Heterologous prime-boost vaccination with adenoviral vector and protein nanoparticles induces both Th1 and Th2 responses against Middle East respiratory syndrome coronavirus.	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 May 2018

http://europepmc.org/abstract/MED/29739720

Heterologous prime-boost vaccination with adenoviral vector and protein nanoparticles induces both Th1 and Th2 responses against Middle East respiratory syndrome coronavirus. (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 May 2018

http://europepmc.org/abstract/MED/29739720

Middle East respiratory syndrome coronavirus

0 references

0 references

1 reference

based on heuristic

inferred from title

Middle East respiratory syndrome

1 reference

based on heuristic

inferred from title

author name string

Seo-Yeon Jung

1

1 reference

Europe PubMed Central

PubMed publication ID

26 May 2018

http://europepmc.org/abstract/MED/29739720

Kyung Won Kang

2

1 reference

Europe PubMed Central

PubMed publication ID

26 May 2018

http://europepmc.org/abstract/MED/29739720

Eun-Young Lee

3

1 reference

Europe PubMed Central

PubMed publication ID

26 May 2018

http://europepmc.org/abstract/MED/29739720

Dong-Won Seo

4

1 reference

Europe PubMed Central

PubMed publication ID

26 May 2018

http://europepmc.org/abstract/MED/29739720

Hong-Lim Kim

5

1 reference

Europe PubMed Central

PubMed publication ID

26 May 2018

http://europepmc.org/abstract/MED/29739720

Hak Kim

6

1 reference

Europe PubMed Central

PubMed publication ID

26 May 2018

http://europepmc.org/abstract/MED/29739720

TaeWoo Kwon

7

1 reference

Europe PubMed Central

PubMed publication ID

26 May 2018

http://europepmc.org/abstract/MED/29739720

Hye-Lim Park

8

1 reference

Europe PubMed Central

PubMed publication ID

26 May 2018

http://europepmc.org/abstract/MED/29739720

Hun Kim

9

1 reference

Europe PubMed Central

PubMed publication ID

26 May 2018

http://europepmc.org/abstract/MED/29739720

Sang-Myeong Lee

10

1 reference

Europe PubMed Central

PubMed publication ID

26 May 2018

http://europepmc.org/abstract/MED/29739720

Jae-Hwan Nam

11

1 reference

Europe PubMed Central

PubMed publication ID

26 May 2018

http://europepmc.org/abstract/MED/29739720

language of work or name

0 references

publication date

5 May 2018

1 reference

Europe PubMed Central

PubMed publication ID

26 May 2018

http://europepmc.org/abstract/MED/29739720

1 reference

Europe PubMed Central

PubMed publication ID

26 May 2018

http://europepmc.org/abstract/MED/29739720

Middle East respiratory syndrome coronavirus: another zoonotic betacoronavirus causing SARS-like disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2018.04.082

7 January 2021

Dipeptidyl Peptidase 4 Distribution in the Human Respiratory Tract: Implications for the Middle East Respiratory Syndrome

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2018.04.082

7 January 2021

Coronaviruses - drug discovery and therapeutic options.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2018.04.082

7 January 2021

Structure of MERS-CoV spike receptor-binding domain complexed with human receptor DPP4

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2018.04.082

7 January 2021

Purified coronavirus spike protein nanoparticles induce coronavirus neutralizing antibodies in mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2018.04.082

7 January 2021

MERS-CoV spike protein: Targets for vaccines and therapeutics

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2018.04.082

7 January 2021

Middle East respiratory syndrome coronavirus spike protein delivered by modified vaccinia virus Ankara efficiently induces virus-neutralizing antibodies

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2018.04.082

7 January 2021

Immunogenicity of an adenoviral-based Middle East Respiratory Syndrome coronavirus vaccine in BALB/c mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2018.04.082

7 January 2021

Systemic and mucosal immunity in mice elicited by a single immunization with human adenovirus type 5 or 41 vector-based vaccines carrying the spike protein of Middle East respiratory syndrome coronavirus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2018.04.082

7 January 2021

Protective Efficacy of Recombinant Modified Vaccinia Virus Ankara Delivering Middle East Respiratory Syndrome Coronavirus Spike Glycoprotein

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2018.04.082

7 January 2021

ChAdOx1 and MVA based vaccine candidates against MERS-CoV elicit neutralising antibodies and cellular immune responses in mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2018.04.082

7 January 2021

A truncated receptor-binding domain of MERS-CoV spike protein potently inhibits MERS-CoV infection and induces strong neutralizing antibody responses: implication for developing therapeutics and vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2018.04.082

7 January 2021

Intranasal vaccination with recombinant receptor-binding domain of MERS-CoV spike protein induces much stronger local mucosal immune responses than subcutaneous immunization: Implication for designing novel mucosal MERS vaccines.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2018.04.082

7 January 2021

Optimization of antigen dose for a receptor-binding domain-based subunit vaccine against MERS coronavirus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2018.04.082

7 January 2021

Receptor-binding domain-based subunit vaccines against MERS-CoV

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2018.04.082

7 January 2021

MERS-CoV spike nanoparticles protect mice from MERS-CoV infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2018.04.082

7 January 2021

A synthetic consensus anti-spike protein DNA vaccine induces protective immunity against Middle East respiratory syndrome coronavirus in nonhuman primates

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2018.04.082

7 January 2021

Evaluation of candidate vaccine approaches for MERS-CoV.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2018.04.082

7 January 2021

Peptide vaccines against cancer, infectious diseases, and conception

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2018.04.082

7 January 2021

Rapid generation of a mouse model for Middle East respiratory syndrome

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2018.04.082

7 January 2021

The paradigm of Th1 and Th2 cytokines: its relevance to autoimmunity and allergy

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2018.04.082

7 January 2021

Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2018.04.082

7 January 2021

Adenoviral vectors persist in vivo and maintain activated CD8+ T cells: implications for their use as vaccines.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2018.04.082

7 January 2021

CD8+ T cell responses following replication-defective adenovirus serotype 5 immunization are dependent on CD11c+ dendritic cells but show redundancy in their requirement of TLR and nucleotide-binding oligomerization domain-like receptor signaling

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2018.04.082

7 January 2021

Adenoviral vector immunity: its implications and circumvention strategies

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2018.04.082

7 January 2021

Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: efficient human cell infection and bypass of preexisting adenovirus immunity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2018.04.082

7 January 2021

Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2018.04.082

7 January 2021

Recent advances in the development of HIV-1 vaccines using replication-incompetent adenovirus vectors

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2018.04.082

7 January 2021

Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2018.04.082

7 January 2021

Adenovirus complexed with polyethylene glycol and cationic lipid is shielded from neutralizing antibodies in vitro

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2018.04.082

7 January 2021

Oral Vaccination of Mice with Adenoviral Vectors Is Not Impaired by Preexisting Immunity to the Vaccine Carrier

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2018.04.082

7 January 2021

Nasal delivery of an adenovirus-based vaccine bypasses pre-existing immunity to the vaccine carrier and improves the immune response in mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2018.04.082

7 January 2021

Recovery from the Middle East respiratory syndrome is associated with antibody and T-cell responses.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2018.04.082

7 January 2021

Adenovirus vector-induced immune responses in nonhuman primates: responses to prime boost regimens

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2018.04.082

7 January 2021

Cellular immune responses of healthy individuals to intradermal administration of an E1-E3- adenovirus gene transfer vector

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2018.04.082

7 January 2021

Replication-defective adenovirus serotype 5 vectors elicit durable cellular and humoral immune responses in nonhuman primates

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2018.04.082

7 January 2021

Redox-active protein thioredoxin prevents proinflammatory cytokine- or bleomycin-induced lung injury.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2018.04.082

7 January 2021

Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2018.04.082

7 January 2021

Combined virus-like particle and fusion protein-encoding DNA vaccination of cotton rats induces protection against respiratory syncytial virus without causing vaccine-enhanced disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2018.04.082

7 January 2021

RSV vaccine-enhanced disease is orchestrated by the combined actions of distinct CD4 T cell subsets

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2018.04.082

7 January 2021

Poly (lactic-glycolic) acid copolymer encapsulation of recombinant adenovirus reduces immunogenicity in vivo

1 reference

https://pubmed.ncbi.nlm.nih.gov/29739720

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1016/J.VACCINE.2018.04.082

1 reference

Europe PubMed Central

PubMed publication ID

26 May 2018

http://europepmc.org/abstract/MED/29739720

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 May 2018

http://europepmc.org/abstract/MED/29739720

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q54217812&oldid=1711423338"